Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Tert-Butanol SCHEMBL8113356 | 0.97 | ALDH1A1 (0.53) | ALDH1A1RECQL | |
| Tetrahydrofuran SCHEMBL711363 | 0.94 | ALDH1A1 (0.57) | ALDH1A1RECQL | |
| Tetrahydrofuran SCHEMBL10597993 | 0.90 | ALDH1A1 (0.53) | ALDH1A1RECQL | |
| Tetrahydrofuran SCHEMBL11173089 | 0.90 | ALDH1A1 (0.53) | ALDH1A1RECQL | |
| Tetrahydrofuran SCHEMBL3464478 | 0.90 | ALDH1A1 (0.53) | ALDH1A1RECQL | |
| Tetrahydrofuran SCHEMBL29094293 | 0.88 | ALDH1A1 (0.50) | ALDH1A1RECQL | |
| Methyl Alcohol SCHEMBL9304289 | 0.87 | — | — | |
| Methyl Alcohol SCHEMBL1534171 | 0.87 | ALDH1A1 (0.67) | ALDH1A1 | |
| Cyclohexane SCHEMBL11380245 | 0.87 | ALDH1A1 (0.67) | ALDH1A1 | |
| Tert-Butanol SCHEMBL7231217 | 0.86 | ALDH1A1 (0.42) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780992-B2 | 5-(4-(2-(2,4-DIMETHYL-6-OXO-1,6-DIHYDRO-1-PYRIMIDINYL) -ETHOXY)PHENYL METHYL)THIAZOLIDINE-2,4-DIONE FOR EXAMPLE; ALSO OXAZOLIDINE-2,4-DIONE, AND 1,2,4-OXADIAZOLIDINE-3,5-DIONE DERIVATIVES; REDUCING BLOOD GLUCOSE LEVELS | DR. REDDY'S LABORATORIES LTD. (IN) | 2004-08-24 | — | — | US | disclosed |
| US-20020123502-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY-CHEMINOR, INC. | 2002-09-05 | — | — | US | disclosed |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | DR. REDDY'S RESEARCH FOUNDATION & REDDY- CHEMINOR, INC. | 2001-10-18 | — | — | US | disclosed |
| EP-0958296-A1 | NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1999-11-24 | — | — | EP | disclosed |
| WO-1997041097-A2 | NOVEL HETEROCYCLIC COMPOUNDS PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED DISEASES | DR. REDDY'S RESEARCH FOUNDATION (IN) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020123502-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | ALDH1A1 829/4885RECQL 1877/4885 |
| US-20010031759-A1 | Novel heterocyclic compounds, process for their preparation and pharmaceutical compounds containing them and their use in the treatment of diabetes and related diseases | IAPP, GPR119, CYP11B1 | ALDH1A1 808/4885RECQL 1876/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.